Design Characteristics and Risk of Bias of Pivotal Trials Supporting Approval of Hematological Drugs By FDA, 2008-2022: Cross Sectional Analysis

Introduction: The approval of hematological drugs by the US Food and Drug Administration (FDA) relies on rigorous evaluation through pivotal trials. To gain insights into the quality and potential bias in these trials, we conducted a cross-sectional analysis of FDA-approved hematological drugs from...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.3695-3695
Hauptverfasser:	Khan, Sara, Sohail, Aruba, Hassan, Maryum, Ukrani, Janta, Fatima, Areej, Farooq, Muhammad, Kumar, Kapisthalam S.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!